Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)

SHE:002550 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	613.38	439.95	576.23	409.26	617.81	516.11
Short-Term Investments	-	192.9	64.95	-	-	-
Trading Asset Securities	145.43	273.83	71.98	67.48	68.23	234.28
Cash & Short-Term Investments	758.81	906.67	713.16	476.73	686.03	750.39
Cash Growth	14.73%	27.13%	49.59%	-30.51%	-8.58%	-13.35%
Accounts Receivable	366.93	274.25	275.52	632.87	447.67	461.88
Other Receivables	23.62	23.24	16.9	2.48	2.56	4.81
Receivables	390.54	297.48	292.42	635.35	450.23	466.69
Inventory	357.93	426.81	602.01	536.48	400.63	315.97
Prepaid Expenses	-	-	-	-	0.01	0.01
Other Current Assets	298.18	62.73	18.39	38.72	33.04	23.96
Total Current Assets	1,805	1,694	1,626	1,687	1,570	1,557
Property, Plant & Equipment	544	563.6	561.27	616.39	611.77	599.56
Long-Term Investments	85.5	160.08	203.22	156.78	40.56	6.71
Goodwill	11.14	11.14	11.14	11.14	11.14	11.14
Other Intangible Assets	108.54	109.32	113.14	100.86	106.92	114.42
Long-Term Deferred Tax Assets	67.11	75.26	90.53	101.49	99.42	105.52
Long-Term Deferred Charges	152.38	138.04	93.77	60.33	46.85	38.14
Other Long-Term Assets	97.94	79.31	67.05	71.67	21.81	19.27
Total Assets	2,872	2,830	2,766	2,806	2,508	2,452
Accounts Payable	54.01	88.64	41.18	45.97	71.23	106.25
Accrued Expenses	30.3	88.06	89.7	101.94	99.55	96.63
Short-Term Debt	19.42	21.49	56.31	103.05	93.56	41.85
Current Income Taxes Payable	-	1.53	0.64	0.05	-	15.02
Current Unearned Revenue	2.85	9.68	9.71	15.58	19.67	11.86
Other Current Liabilities	57.34	14	8.28	11.63	12.34	19.38
Total Current Liabilities	163.92	223.39	205.81	278.22	296.35	290.98
Long-Term Unearned Revenue	88.29	86.46	81.85	89.35	93.42	94.87
Long-Term Deferred Tax Liabilities	3.47	4.02	4.52	4.96	0.47	0.5
Total Liabilities	255.69	313.87	292.17	372.53	390.24	386.35
Common Stock	1,280	1,280	1,280	1,280	1,280	1,280
Additional Paid-In Capital	41.65	41.65	41.65	36.29	29.38	25.58
Retained Earnings	1,477	1,369	1,163	1,134	960.89	929.79
Treasury Stock	-170.86	-170.86	-30.09	-	-145.05	-154.38
Comprehensive Income & Other	-2.21	-2.42	0.36	-0.06	2.23	-0.88
Total Common Equity	2,626	2,517	2,455	2,450	2,127	2,080
Minority Interest	-9.34	-0.87	18.98	-16.95	-9.09	-14.56
Shareholders' Equity	2,616	2,517	2,474	2,433	2,118	2,065
Total Liabilities & Equity	2,872	2,830	2,766	2,806	2,508	2,452
Total Debt	19.42	21.49	56.31	103.05	93.56	41.85
Net Cash (Debt)	739.39	885.19	656.85	373.69	592.48	708.54
Net Cash Growth	15.63%	34.76%	75.78%	-36.93%	-16.38%	35.81%
Net Cash Per Share	0.58	0.70	0.51	0.29	0.49	0.59
Filing Date Shares Outstanding	1,250	1,250	1,275	1,280	1,280	1,280
Total Common Shares Outstanding	1,250	1,250	1,275	1,280	1,280	1,280
Working Capital	1,642	1,470	1,420	1,409	1,274	1,266
Book Value Per Share	2.10	2.01	1.93	1.91	1.66	1.63
Tangible Book Value	2,506	2,397	2,331	2,338	2,009	1,954
Tangible Book Value Per Share	2.01	1.92	1.83	1.83	1.57	1.53
Buildings	-	498.75	498.75	525.73	524.28	448.65
Machinery	-	568.44	558.3	504.84	461.29	426.63
Construction In Progress	-	61.25	8.19	54.1	39.24	76.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.